Analyst Rating Update on InspireMD (NSPR)

InspireMD (NSPR) : 1 brokerage houses believe that InspireMD (NSPR) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 1 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.

For the current week, the company shares have a recommendation consensus of Buy.


InspireMD (NYSEMKT:NSPR): During Wednesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $0.18 and $0.18 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $0.19. The buying momentum continued till the end and the stock did not give up its gains. It closed at $0.19, notching a gain of 1.82% for the day. The total traded volume was 1,018,209 . The stock had closed at $0.18 on the previous day.

InspireMD, Inc. is a medical device company. The Company is focused on the development and commercialization of its MicroNet stent platform technology for the treatment of complex coronary and vascular disease. The Companys MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. The Companys MGuard coronary products combining MicroNet and a bare-metal stent (MGuard Prime Embolic Protection Stent (EPS)) are marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The Companys second product CGuard carotid embolic prevention system (EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease. The Company is also developing a pipeline of other products and additional applications by leveraging its MicroNet technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.